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Giovanni Pedrazzini6, André Vuilliomenet7, Daniel Weilenmann8, Hans Rickli8, Kim
Wadt HansenID
1, Peter Rickenbacher9, David Conen1,10, Christian Müller1,
Stefan Osswald1, Nicole Gilgen1, Christoph Kaiser1
1 Cardiology, University Hospital Basel, University Basel, Basel, Switzerland, 2 Cardiology, Gentofte
University Hospital Copenhagen, Hellerup, Denmark, 3 Cardiology, Elisabeth-Krankenhaus, Essen,
Germany, 4 Cardiology, University Hospital Innsbruck and Klinikum Klagenfurt am Wörthersee, Innsbruck
and Klagenfurt am Wörthersee, Austria, 5 Cardiology, Triemli Hospital, Zürich, Switzerland, 6 Cardiology,
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Abstract
Background
Dual antiplatelet therapy (DAPT) prevents thrombotic events after coronary stent implanta-
tion but may induce bleedings, specifically in elderly patients. However, a competitive risk
analysis is lacking.
Objectives
To assess the determinants of major bleeding and the balance between the competing risks
of major bleeding and thrombotic events during prasugrel-based DAPT after stent
implantation.
Methods
Overall, 2,291 patients randomized to drug-eluting or bare metal stents and treated with pra-
sugrel 10mg/day for 1 year were followed over 2 years for major bleeding (BARC 3/5) and
thrombotic events (cardiac death, myocardial infarction, definitive/probable stent thrombo-
sis). Prasugrel dose was reduced to 5mg in patients >75 years and/or <60kg. Predictors of
major bleeding and competing risks of major bleeding and thrombotic events were
assessed.
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Results
Two-year rates of major bleeding and thrombotic events were 2.9% and 9.0%, respectively.
The only independent predictor of major bleeding was age (hazard ratio per year increase
1.05 [1.02,1.07], p<0.001). The relationship between major bleeding and age was non-lin-
ear, with lowest hazard ratios at 57 years and an exponential increase only above 65 years.
In contrast, the relationship between thrombotic events and age was linear and continuously
increasing with older age. While the competing risk of thrombotic events was higher than
that of major bleeding in younger patients, the two risks were similar in older patients. After
discontinuation of prasugrel, bleeding events leveled off in all patients, while thrombotic
events continued to increase.
Conclusions
In prasugrel-based DAPT, age is the strongest risk factor for major bleeding, increasing
exponentially >65 years. In younger patients, thrombotic events represent a higher risk than
bleeding, while thrombotic and bleeding risks were similar in older patients. Important clini-
cal implications relate to prasugrel dose in the elderly, duration of DAPT and the competing
risk balance necessitating individualized treatment decisions.
Introduction
Dual antiplatelet therapy (DAPT) with aspirin and a platelet P2Y12 adenosine diphosphate
receptor antagonist inhibits platelet aggregation and prevents recurrent ischemia and stent
thrombosis. The combination of aspirin and clopidogrel has shown a clear benefit against aspi-
rin alone regarding thrombotic events [1, 2] and entered guideline recommendations [3].
However, since up to one third of patients are low-responders or even resistant to clopidogrel
[4], newer compounds such as prasugrel and ticagrelor have been developed [5, 6].
DAPT after percutaneous coronary intervention (PCI) entails an increased risk for major
bleeding in both unselected patients [7] and patients with acute coronary syndromes (ACS) [8,
9]. Although prasugrel is superior to clopidogrel for ACS patients after PCI [10] based on the
results of TRITON–TIMI 38 [6], it was associated with more bleedings, particularly in patients
>75 years, and therefore, has not been recommended in this age group [11, 12]. However, a
reduced dose of 5mg daily for patients <60kg was proposed based on ancillary studies of TRI-
TON-TIMI 38 [13, 14] and entered label information of the European Medicines Agency [11].
Although actually not recommended for patients >75 years of age, prasugrel is used in this age
group in many centers, mainly with the reduced-dose regimen of 5mg daily. The incidence of
major bleeding in patients >75 years of age treated with low-dose prasugrel has been reported
in a subgroup analysis of the TRILOGY-ACS study and was not different to clopidogrel [15].
However, the exact benefit-risk balance between the prevention of thrombotic events and the
induction of major bleeding for prasugrel-based DAPT in different age groups is unknown.
In the multicenter BASKET-PROVE II trial, PCI patients were treated with bleeding-risk
dose-adjusted prasugrel-based DAPT, irrespective of clinical indication and stent type [16].
Prasugrel was stopped after one year and patients followed for another 12 months. In this con-
text, we performed a retrospective analysis of prospectively collected long-term findings to
identify predictors of major bleeding and assess the competing risks of major bleeding and
thrombotic events in the different age groups.
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Materials and methods
Study design
This is a retrospective, observational analysis of the randomized BASKET PROVE II trial that
enrolled patients between April 2010 and May 2012. BASKET-PROVE II [16, 17] was a pro-
spective, controlled, randomized multicenter trial that aimed to define the efficacy and safety
of biodegradable-polymer biolimus A9-eluting stents (Nobori, Terumo, Somerset NJ) com-
pared to durable-polymer everolimus-eluting stents (Xience Prime, Abbott Vascular, Abbott
Park IL) and thin-strut silicone-carbide coated bare-metal stents (BMS; Prokinetik, Biotronik,
Berlin, Germany) [17]. All patients received a prasugrel-based DAPT after stent implantation
and were followed for two years. The patient flow chart is depicted in Fig 1.
Written informed consent was obtained from all patients. Elective patients were enrolled
after giving written informed consent, while urgent or emergent patients first gave oral con-
sent documented by a medical person not involved in the trial to avoid any time delay due to
the enrolment procedure, and provided written informed consent after the intervention. The
following Independent Ethics Committees were consulted: Ethikkommission beider Basel
EKBB, Hebelstrasse 53, 4056 Basel, Switzerland; De Videnskabsetiske Komiteer I Region
Hovedstaden, Kongens Vænge 2, 3400 Hillerød, Denmark; Ethikkommission der Medizi-
nischen Universität Innsbruck, Innrain 43, 6020 Innsbruck, Austria; Ethikkommission der
Fig 1. Patient flow chart. BMS indicates bare-metal stent; BP-DES, biodegradable-polymer drug-eluting stent; CABG, coronary artery bypass graft; and
DP-DES: durable-polymer drug-eluting stent.
https://doi.org/10.1371/journal.pone.0210821.g001
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Ärztekammer Nordrhein, Tersteegenstrasse 9, 40474 Düsseldorf, Germany; Comitato etico
cantonale, Via Orico 5, 6501 Bellinzona, Switzerland; Ethikkommission des Kantons St.Gallen,
Kantonsspital/Flurhof 7, Rorschacherstrasse 95, 9007 St.Gallen, Switzerland; Kantonale Ethik-
kommission Zürich KEK (Abteilung 4), Sonneggstrasse 12, 8091 Zürich, Switzerland; Kanto-
nale Ethikkommission Aargau, Bachstrasse 15, 5001 Aarau, Switzerland. The local ethics
committees in each center approved the study protocol. The study was initially approved by
the EKBB on November 20th, 2009. The first patient entered the study on April 1st, 2010, the
last patient left the study on June 30th, 2014. The study complies with the Declaration of
Helsinki.
The study was initially registered in the EUDRACT-registry on August 25th, 2009 before
start of patient recruitment (EudraCT Number 2009-015616-18). In addition, the trial was reg-
istered in the clinicaltrials.gov registry before the study start. Unfortunately, it was registered
twice under two different identifiers, i.e., under the project numbers NCT01097187 and
NCT01166685 in November 2009. To avoid duplicity, the registration NCT01097187 (Record
2009-01516-18) was deleted and the registration NCT01166685 changed and released anew
(July 2010).
Patients
The study enrolled all-comer patients undergoing PCI with stents�3mm in diameter. Exclu-
sion criteria included in-stent restenosis, stent thrombosis, bypass graft interventions, unpro-
tected main stem lesions, cardiogenic shock, planned surgery within 12 months, oral
anticoagulation, history of or active bleeding disorders, known hypersensitivity to antiplatelet
medication, no follow-up possible, no compliance expected or any known cerebrovascular
accident.
Study procedures and treatment
PCI was performed according to standard techniques at the discretion of the interventional
cardiologist in charge. If not already treated with the drugs, all patients received a loading dose
of 250 to 500mg aspirin i.v. and 60mg prasugrel p.o., followed by a maintenance dose of
100mg aspirin and 10mg prasugrel p.o. daily over 12 months. Prasugrel was adjusted to the
bleeding risk of patients, i.e., in patients >75 years of age and/or <60kg of body weight, prasu-
grel maintenance dose was reduced to 5mg p.o. [6]. Prasugrel was prescribed for 12 months in
all ACS patients and/or patients receiving drug-eluting stents (DES) and for one month in sta-
ble coronary artery disease patients receiving BMS. To assure adherence to DAPT, patients
were given the drug in monthly packages at regular intervals from the study centers. No fur-
ther prasugrel was provided after 12 months. All patients were prescribed statin therapy. No
routine angiographic follow-up was allowed unless clinically indicated.
Endpoints and definitions
The primary endpoint for this analysis was time to major bleeding not related to coronary
artery bypass graft surgery within 24±2 months, as defined according to the Bleeding Aca-
demic Research Consortium (BARC) [18] criteria 3 and 5. The main secondary endpoint was
time to thrombotic events, i.e., cardiac death, non-fatal myocardial infarction, and probable/
definite stent thrombosis, within 24±2 months. Cardiac death was defined as any death not
clearly due to a non-cardiac cause. Myocardial infarction was defined as described previously
[19] and stent thrombosis according to the Academic Research Consortium criteria [20].
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Statistical analyses
All analyses were performed according to the intention-to-treat principle. Baseline characteris-
tics are reported as counts and percentages or means±standard deviation. Continuous vari-
ables were compared using Wilcoxon’s rank sum test, categorical variables using Fisher’s exact
test. Time-to-event analyses were carried out, using the Kaplan-Meier estimator and Cox pro-
portional hazards models, stratifying for center. The following variables were investigated as
predictors for major bleeding: sex, age, weight, diabetes mellitus, renal disease, stent type, gly-
coprotein IIb/IIIa inhibitor use, prasugrel dose, and indication for PCI. In order to find the
smallest combination of predictors for major bleeding, a backward model selection approach
based on Akaike’s information criterion was applied. The selection process started with the
maximal model including all of the above listed predictors plus the interaction term between
age and prasugrel dose. No further interactions were considered. Only linear terms were
explored. As first step, single predictors were removed step by step, until the Akaike’s informa-
tion criterion did not decrease any further (automatic backwards selection). As second step,
this model was further simplified by step-wise removal of the remaining predictors (manual
backwards selection). Akaike’s information criterion was allowed to increase slightly, i.e. no
more than 2 units for each removed predictor compared to the model with the minimal
Akaike’s information criterion (Δ<2.0). No imputation of missing data was performed. For
the model selection procedure only patients without any missing values in the predictor vari-
ables were used (n = 2232). The resulting final model was then refitted using all 2291 patients.
In order to explore the functional form of the relationship between major bleeding and age,
several Cox models considering age as categorical or non-linear predictor were fit. Based on
previous literature, age was initially categorized as<75 years and�75 years. Then, a non-lin-
ear relationship with age was explored. The observed proportions of events with 95% confi-
dence intervals were plotted for different age groups (5-year classes, 10-year classes, and
deciles) and explored visually. Finally, age was modeled more flexibly using natural cubic
regression splines. The degrees of freedom, and thus the number and position of knots, were
obtained by minimizing the Bayesian information criterion [21]. Pointwise nonparametric
hazard ratios with 95% confidence intervals were estimated, and the smoothing hazard ratio
curve with 95% confidence bands was shown for the observed age range.
For the competing risk analysis, thrombotic events were considered a competing risk to
major bleeding, in the sense that the occurrence of a thrombotic event modifies the chances
for the occurrence of major bleeding and vice versa. Therefore, we examined whether the
effects of age differed between the two types of events or risks, i.e. were cause-specific. Cumula-
tive incidence curves for each event type are shown overall and according to age dichotomized
at 65 years. Estimates are based on the Aalen-Johansen estimator, an extension of the Kaplan-
Meier estimator to the case of multiple, competing risks [22]. Patients who experienced the
competing event, i.e. had a thrombotic event first, were censored at the time of occurrence of
the competing event. Regression splines were fit as described before. Further, cause-specific
hazards were compared between patients <65 and�65 years for each event and the relative
hazards for the two competing events were compared within each age group by duplicating
the data set (two rows per patient, one for each event type). The duplicated data set was then
analyzed using a Cox proportional hazard model with event type and age group and their
interaction as predictors. Model assumptions have been checked by inspection of the Schoen-
feld residuals and deviance residuals.
All analyses were performed with the statistical software system R version 3.1.0.[23]. A p-
value <0.05 indicated statistical significance.
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Results
Overall, 2291 patients were enrolled in BASKET PROVE II. The median age of all patients was
63.2 years (range 28.0 to 91.2 years), 77.7% were men, and 28.8% presented with ST-elevation
myocardial infarction, 34.4% with Non-ST-elevation ACS and 36.9% with stable coronary dis-
ease [16]. Two-year rates of major bleeding and thrombotic events were 2.9% and 9.0%,
respectively.
Age was the only independent predictor of major bleeding (hazard ratio 1.05 per year, 95%
confidence interval 1.02, 1.07, p<0.001), while none of the other variables being assessed in
the model reached statistical significance. The functional relationship of age with major bleed-
ing showed a J-shaped curve with the lowest risk at the age of 57 years. Below 57 years, there
was a somewhat higher risk for major bleeding, although the hazard ratio was not significantly
increased (Fig 2A, Table 1). Above 57 years, there was a sharp and exponential increase in the
risk of major bleeding that was statistically significant after the age of 65 years contrasting to
the lack of a significant change in the risk below 57 years. The risk relation with age was differ-
ent for thrombotic events with a steady increase with increasing age (Fig 2B, Table 1). Based
on these findings patients were divided into younger and older than 65 years (Table 2). Base-
line characteristics of these two groups showed that older patients were less frequently male
and had a lower weight, suffered more often from diabetes mellitus and arterial hypertension
but were less frequently smoking than younger patients <65 years. Older patients had under-
gone more prior revascularization procedures and had more known renal disease than youn-
ger patients. Older patients underwent PCI more frequently for stable angina and less
frequently for ST-elevation MI than younger patients. Glycoprotein-IIb/IIIa-inhibitors were
used less often in older than younger patients. The hazard ratio for major bleeding in patients
older vs. younger than 65 years was 2.21 (95% confidence interval 1.33, 3.65, p<0.001).
Fig 2. Nonparametric estimates of the dependence of the case-specific hazard ratios for major non-CABG bleeding (Fig 2A) and thrombotic events (Fig
2B) on age. Log hazard ratios with 95% confidence band are shown. The hazard ratios are relative to the age with the lowest hazard (major non-CABG
bleeding: indicated knot = 57 years; thrombotic events: minimal age = 28 years). CABG, coronary artery bypass graft; LnHR, log hazard ratio; Z, specific value
of age on x-axis; Zref, reference value of age with lowest hazard, i.e. indicated knot.
https://doi.org/10.1371/journal.pone.0210821.g002
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Cumulative incidence curves for major bleeding and thrombotic events are shown in Fig 3.
The rates of major bleeding increased during the initial year after stent implantation, i.e. dur-
ing treatment with prasugrel and acetylsalicylic acid, but leveled off afterwards, i.e. after dis-
continuation of prasugrel, while rates of thrombotic events increased continuously until the
end of the follow-up. A detailed analysis of these curves relative to the two age groups shows a
persistently higher hazard for major bleeding events in patients�65 vs. <65 years of age dur-
ing the entire follow-up (hazard ratio 2.34, 95% confidence interval 1.40, 3.90, p = 0.001, Fig
4A). In contrast, the hazard for thrombotic events between the two age groups were similar
Table 1. Baseline characteristics in patients<65 and�65 years of age.
Patients <65 Years Patients�65 Years p
n 1286 (56.1) 1005 (43.9)
Demographics and medical history
Age (years) 55.0 (7.1) 73.1 (5.5) <0.001
Sex (male) 1089 (84.7) 691 (68.8) <0.001
Weight (kilogram) 85.0 (15.5) 79.5 (14.2) <0.001
Diabetes mellitus 197 (15.3) 232 (23.1) <0.001
- Insulin-dependent 50 (3.9) 60 (6.0) 0.027
Hypertension 766 (59.6) 757 (75.3) <0.001
Hypercholesterolemia 812 (63.1) 637 (63.4) 0.940
Current smoking 653 (50.8) 165 (16.4) <0.001
Renal disease 32 (2.5) 95 (9.5) <0.001
Prior myocardial infarction 118 (9.2) 93 (9.3) 1.000
Prior PCI 154 (12.0) 153 (15.2) 0.028
Prior CABG 20 (1.6) 39 (3.9) 0.001
Indication for PCI
Stable coronary artery disease 398 (30.9) 447 (44.5) <0.001
Unstable angina pectoris and NSTEMI 450 (35.0) 337 (33.5) 0.493
STEMI 438 (34.1) 221 (22.0) <0.001
Coronary anatomy
Left main disease 6 (0.5) 7 (0.7) 0.655
Left anterior descending artery disease 799 (62.1) 650 (64.7) 0.226
Left circumflex disease 407 (31.6) 377 (37.5) 0.004
Right coronary artery disease 661 (51.4) 532 (52.9) 0.491
Multivessel disease 458 (35.6) 420 (41.8) 0.003
Bifurcation disease 67 (5.2) 54 (5.4) 0.940
Chronic total occlusion 56 (4.4) 30 (3.0) 0.109
Percutaneous coronary intervention
Glycoprotein IIbIIIa inhibitor 204 (15.9) 80 (8.0) <0.001
Stent per segment (n) 1.2 (0.5) 1.3 (0.6) 0.063
Stent per patient (n) 1.5 (0.8) 1.5 (0.8) 0.253
Stent length (mm) 25.9 (16.5) 26.2 (17.6) 0.677
Stent <3.0 mm 51 (4.0) 48 (4.8) 0.401
Max implantation pressure (atm) 15.0 (3.6) 14.5 (3.5) <0.001
Staged procedure 80 (6.2) 67 (6.7) 0.733
PCI, percutaneous coronary intervention; CABG, coronary artery bypass graft; NSTEMI, non-ST-elevation myocardial infarction; STEMI, ST-elevation myocardial
infarction. Baseline characteristics are reported as counts and percentages or means ± standard deviation. Continuous variables were compared using Wolcoxon’s rank
sum test, categorical variables using Fisher’s exact test.
https://doi.org/10.1371/journal.pone.0210821.t001
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(hazard ratio 1.28, 95% confidence interval 0.85, 1.93, p = 0.229; Fig 4B). In younger patients,
the risk of major bleeding was lower than the risk of thrombotic events (hazard ratio 2.04, 95%
confidence interval 1.24, 3.37, p = 0.0050), with notably few major bleeding events but a con-
stant increase in thrombotic events during the 2nd year. In contrast, no difference in the haz-
ards for the two events could be shown in the elderly during the entire follow-up (hazard ratio
1.12, 95% confidence interval 0.74, 1.71, p = 0.593).
Discussion
In this secondary analysis of a major stent trial, the following clinically important points can
be highlighted: First, in patients undergoing stent implantation and treated with prasugrel-
based DAPT, age appeared to be the most relevant predictor of major bleeding. While the risk
of major bleeding increased with older age, the functional relationship with age was clearly
non-linear with the lowest hazard at the age of 57 years and an exponential and significant
increase only after 65 years. Of note, neither prasugrel dose nor patient weight emerged as a
predictor of major bleeding. Second, in contrast to the non-linear relation between major
bleeding and age, the association between thrombotic events and age was linear with a contin-
uous increase in risk with older age. Third, the competing risk analysis showed that the risk
balance was different between the two age groups: Younger patients i.e. patients <65 years of
age, were at a higher risk for thrombotic events than for major bleeding throughout the entire
2 year trial period. In contrast, older patients, i.e. patients�65 years of age, were at a higher
risk for major bleeding during the first year, while after the discontinuation of prasugrel the
risks for both events approximated each other and the risk for thrombotic events became even
more pronounced.
Major bleeding has been recognized as an important prognostic factor after PCI not only in
ACS [8, 24] but also in an unselected PCI population [7]. Case fatality rates for major bleeding
have been described in previous studies and are estimated to be over 12% [8, 24, 25]. Major
Table 2. Pointwise nonparametric estimation of cause-specific hazard ratios for major bleeding and thrombotic events as competing risks according to age.
Age Major Bleeding Thrombotic events
Hazard Ratio 95% Confidence Interval Number of Events/ Patients Hazard Ratio 95% Confindence Interval Number of Events/ Patients
30 4.01 [0.96, 16.78] 0/2 1.05 [1.01, 1.09] 0/2
35 2.72 [0.9, 8.17] 2/9 1.19 [1.03, 1.35] 1/9
40 1.9 [0.86, 4.18] 0/31 1.34 [1.06, 1.68] 2/31
45 1.4 [0.85, 2.34] 1/84 1.51 [1.08, 2.08] 2/84
50 1.13 [0.87, 1.46] 4/183 1.7 [1.12, 2.59] 6/183
55 1.01 [0.95, 1.07] 4/265 1.92 [1.14, 3.19] 4/265
60 1.03 [0.95, 1.11] 5/336 2.16 [1.17, 3.97] 13/336
65 1.21 [1.02, 1.43] 7/379 2.44 [1.2, 4.9] 19/379
70 1.67 [1.31, 2.14] 8/351 2.72 [1.22, 6.11] 9/351
75 2.61 [1.84, 3.74] 8/304 3.06 [1.26, 7.54] 17/304
80 4.53 [2.72, 7.54] 15/220 3.46 [1.28, 9.3] 6/220
85 8.33 [4.1, 16.95] 8/105 3.9 [1.32, 11.59] 12/105
90 15.96 [6.23, 40.85] 2/22 4.39 [1.35, 14.3] 2/22
Hazard ratios are the ratios of the hazard for the respective age (e.g. 30 years) to the lowest hazards estimate (for major bleeding: 57 years; for thrombotic events: 28
years–c.f. Fig 2A and 2B). Number of Events/Patients give the number of observed first events and the number of patients in the respective age class (e.g. age 30 includes
all patients < 30 years, age 35 includes all patients > = 30 years and < 35 years, age 90 includes all patients > 90 years). Please note that hazard ratios are point-wise
model predictions, while number of events/patients summarize observations over age ranges.
https://doi.org/10.1371/journal.pone.0210821.t002
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bleeding is a frequent complication of DAPT and is more prevalent with newer compounds
such as prasugrel and ticagrelor than with clopidogrel, most likely due to their higher and
more consistent antiplatelet activity [5, 6]. The incidence of major bleeding after PCI has been
described to be between 0.4% and 6.6% for different scenarios, with lower rates in stable
patients and higher rates in patients with ACS [7–9, 15, 24, 26]. The association between bleed-
ing and age has been recognized before with a higher risk in the elderly [9, 15, 27], but the
non-linear relationship documented in the present analysis seems remarkable. However, dif-
ferent definitions for major bleeding have been used [28, 29] and make comparisons difficult.
These definitions were developed for different settings, i.e., the more laboratory-based TIMI
[28] and the predominantly clinic-based GUSTO definitions [29] for patients with acute myo-
cardial infarction and thrombolysis and the more unifying BARC definitions specifically for
patients undergoing PCI [18]. Thus, comparisons of bleeding rates between trials have to be
done cautiously, considering the different definitions and patient situations [30].
The present competing risk analysis shows different risk patterns in patients younger and
older than 65 years. While patients younger than 65 years had a bleeding rate that was lower
than the associated thrombotic event rate during DAPT, the opposite was true for patients
Fig 3. Cumulative incidence curves with 95% confidence bands for the competing events of non-CABG major bleeding (red) and thrombotic event (blue)
in all 2,291 patients. CABG, coronary artery bypass graft.
https://doi.org/10.1371/journal.pone.0210821.g003
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older than 65 years of age. During the 2nd year of follow-up, i.e. after DAPT discontinuation,
the bleeding rate no longer increased, but remained higher in older versus younger patients,
whereas the rate of thrombotic events increased continuously and similarly in both age
groups.
Therefore, two key questions in relation to the current use of DAPT in general and prasu-
grel in particular arise. First, our data suggest that the age-cut-off of 75 years for dose reduction
of prasugrel in some previous studies [7, 15] was arbitrary and may have been too high. This
cut-off age to reduce the daily prasugrel dose was selected based on TIMI-38 findings [6] and
subsequently recommended by the European and U.S. authorities [11, 12]. However, the pres-
ent analysis shows that the bleeding risk does not change with age in a linear fashion, but starts
to increase exponentially already at 65 years of age, rather than at 75. This implies that dose
reductions may already be necessary above age 65, questioning current recommendations. Sec-
ond, DAPT in the elderly should be used with caution based on the increased bleeding risk,
but at the same time might be necessary due to the similarly increased thrombotic risk, at least
for a certain period of time. Overall, the continued increase in thrombotic risk argues for a
prolonged duration of DAPT, which was tested in the DAPT trial [31]. It found a benefit of
prolonged treatment with a further reduction of thrombotic events, but only a minority of
patients were in the age group >65 years where the bleeding risk is markedly increased. Thus,
patients older than 65 years of age pose a clinical dilemma, i.e., their exponentially increasing
age-related bleeding risk may outweigh the benefit of reduced thrombotic events. In contrast,
current guidelines recommend shorter DAPT durations for stable patients treated with DES,
which may indeed reduce bleeding complications [32, 33]. This highlights the need for indi-
vidualized treatment decisions based on available scores.
Study limitations
This retrospective analysis has certain inherent limitations. Few patients with stable angina
and treated with a BMS received only 1 month of DAPT, while some patients received prasu-
grel for stable angina. Guidelines at the time of the design of this trial advocated 12 month
DAPT after DES implantation, while current guidelines support shorter DAPT durations in
Fig 4. Cumulative incidence curves with 95% confidence bands for the competing events of non-CABG major bleeding (Fig 4A) and thrombotic event
(Fig 4B) according to age dichotomized at 65 years. Note the significant differences in major bleedings indicated by the not overlapping confidence bands,
but the non-significant differences in thrombotic events. CABG, coronary artery bypass graft.
https://doi.org/10.1371/journal.pone.0210821.g004
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stable patients [33]. Based on the present data, the ideal duration of DAPT cannot be defined
since only the competitive risks regarding bleeding and thrombotic events for 1 year DAPT
were analyzed. Patients generally underwent PCI by femoral route in our study. The use of a
radial access may lead to lower bleeding rates, but mainly with regard to BARC 1 and 2 bleed-
ings (not reported here) and only for a short period of time after PCI. Ways to decrease the
bleeding risk such as the use of the radial approach for PCI and a reduction of treatment time
to 3 months in elective patients and to 6 months in patients treated for ACS receiving DES, as
recommended by current guidelines [33] might be valuable options to further improve out-
comes in high-risk patients undergoing PCI. A caveat remains in the continued increase of
thrombotic events even after drug discontinuation as noted in the present analysis. Finally, we
would like to emphasize that the analyses presented here are secondary analyses and thus of
exploratory nature. Estimates, e.g. hazard ratios, should be interpreted taking the reported
95% confidence intervals into account. Although our results are strongly suggestive for chang-
ing risk patterns depending on patients’ age and thus question current recommendations for
dose reductions, evidence from external validation is needed for confirmation.
Conclusions
In patients undergoing stent implantation treated with prasugrel-based DAPT, age was the
only independent predictor of major bleeding. While the risk of major bleeding increased with
older age, the functional relationship was clearly non-linear with no significant change in the
bleeding hazard up to the age of 57 years and an exponential and significant increase after 65
years. In contrast, there was a continuous age-related increase in the risk of thrombotic events
in all patients up to 2 years. The competitive risk analysis showed that younger patients were at
a higher risk for thrombotic events than for major bleeding. In contrast, older patients were at
higher risk for major bleeding during the first year, while thereafter the risk curves for both
events crossed indicating that the risk for thrombotic events became more predominant.
These findings imply that prasugrel standard dose may be appropriate up to 65 years of age.
However, a dose reduction may be appropriate above 65 years but not only above 75 as recom-
mended. The present competing risk analysis identifies an important clinical dilemma for
daily practice, i.e., the continued increase in the risk of thrombotic events after the discontinu-
ation of DAPT vs. the elevated bleeding risk on continued DAPT. Based on our data, the expo-
nential increase in the risk of major bleeding may outweigh the benefit of prolonged DAPT at
least in high-risk patients�65 years of age. Therefore, our data highlight the need for an indi-
vidualized treatment approach in these patients.
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